Spinocerebellar Ataxia Type 2Symptoms, Doctors, Treatments, Advances & More
Spinocerebellar Ataxia Type 2 Overview
Learn About Spinocerebellar Ataxia Type 2
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of Utah Hospital Neurology Department
Stefan Pulst is a Neurologist practicing medicine in Salt Lake City, Utah. Dr. Pulst is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia Type 2. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Pulst is board certified in American Board Of Psychiatry And Neurology. Dr. Pulst is currently accepting new patients.
Georg Auburger practices practicing medicine in Frankfurt Am Main, Germany. Mr. Auburger is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 2. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 2, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia.
Mohammed Faruq practices practicing medicine in Delhi, India. Mr. Faruq is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 2. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Harding Ataxia.
Summary: Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.